Investor Presentaiton
Top-tier talent
Differentiated process
Scalable platform
Cytokinetics case study: hypertrophic cardiomyopathy (HCM)
Background
Cytokinetics
Biotech focused on muscle
biology, cardiology and
neuromuscular diseases
Drug pipeline in heart failure,
HCM, SMA
Corporate headquarters in San
Francisco, California
Royalty Pharma partnership in
February 2017 for omecamtiv
mecarbil (heart failure)
Challenge
What is the size of the commercial
market for aficamten in HCM?
Key considerations
Novel
disease area
No FDA
approved therapies
Likely second
to market
Global market
development
Royalty Pharma solution
Conducted detailed market evaluation
•
Unique Royalty Pharma capability
Adds conviction to investment process
100% internal team and proprietary data
Enhances engagement, value to partner
Analyzed medical claims and
electronic health data
>150
commercial &
gov't payers
~90m
patient lives
~20k
practices
ROYALTY PHARMA SMA: Spinal Muscular Atrophy
59View entire presentation